JP2008532487A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008532487A5 JP2008532487A5 JP2007554188A JP2007554188A JP2008532487A5 JP 2008532487 A5 JP2008532487 A5 JP 2008532487A5 JP 2007554188 A JP2007554188 A JP 2007554188A JP 2007554188 A JP2007554188 A JP 2007554188A JP 2008532487 A5 JP2008532487 A5 JP 2008532487A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- fragment
- cancer
- mutation
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims 38
- 230000035772 mutation Effects 0.000 claims 21
- 102220510527 Retinoic acid receptor alpha_L102Y_mutation Human genes 0.000 claims 19
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 14
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 14
- 206010028980 Neoplasm Diseases 0.000 claims 12
- 102220582002 Phospholipid-transporting ATPase ABCA3_N53Q_mutation Human genes 0.000 claims 12
- 201000011510 cancer Diseases 0.000 claims 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims 11
- 102220320590 rs1554306309 Human genes 0.000 claims 10
- 102220470494 Proteasome subunit beta type-3_M34L_mutation Human genes 0.000 claims 8
- 102220183908 rs9282732 Human genes 0.000 claims 8
- 206010009944 Colon cancer Diseases 0.000 claims 6
- 208000009956 adenocarcinoma Diseases 0.000 claims 6
- 239000002246 antineoplastic agent Substances 0.000 claims 6
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 6
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 4
- 102220492950 Nuclear RNA export factor 1_R91A_mutation Human genes 0.000 claims 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 4
- 206010038389 Renal cancer Diseases 0.000 claims 4
- 102220521977 THAP domain-containing protein 1_T28A_mutation Human genes 0.000 claims 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 4
- 201000010982 kidney cancer Diseases 0.000 claims 4
- 201000007270 liver cancer Diseases 0.000 claims 4
- 208000014018 liver neoplasm Diseases 0.000 claims 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 201000002528 pancreatic cancer Diseases 0.000 claims 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 4
- 201000009030 Carcinoma Diseases 0.000 claims 3
- 102220497694 Ragulator complex protein LAMTOR4_K51A_mutation Human genes 0.000 claims 3
- 102220469751 Voltage-dependent L-type calcium channel subunit beta-2_G50K_mutation Human genes 0.000 claims 3
- 230000004071 biological effect Effects 0.000 claims 3
- 201000000053 blastoma Diseases 0.000 claims 3
- 201000008184 embryoma Diseases 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 102200016465 rs104894275 Human genes 0.000 claims 3
- 102220267369 rs760252179 Human genes 0.000 claims 3
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 208000010667 Carcinoma of liver and intrahepatic biliary tract Diseases 0.000 claims 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 2
- 206010073069 Hepatic cancer Diseases 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 2
- 102220497574 Leukotriene B4 receptor 1_N52Q_mutation Human genes 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 229930012538 Paclitaxel Natural products 0.000 claims 2
- 102220489100 Phosphatidylinositol transfer protein alpha isoform_N89L_mutation Human genes 0.000 claims 2
- 102220644061 Prostaglandin E synthase 3_E12V_mutation Human genes 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 108010035587 R13Q Proteins 0.000 claims 2
- 206010061934 Salivary gland cancer Diseases 0.000 claims 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 206010047741 Vulval cancer Diseases 0.000 claims 2
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims 2
- 230000001093 anti-cancer Effects 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 2
- 201000002250 liver carcinoma Diseases 0.000 claims 2
- 230000001394 metastastic effect Effects 0.000 claims 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims 2
- 229960001592 paclitaxel Drugs 0.000 claims 2
- 229960004641 rituximab Drugs 0.000 claims 2
- 102220069325 rs141790557 Human genes 0.000 claims 2
- 102220274413 rs143950084 Human genes 0.000 claims 2
- 102220243676 rs1555601019 Human genes 0.000 claims 2
- 102220275989 rs1556435940 Human genes 0.000 claims 2
- 102200092684 rs371769427 Human genes 0.000 claims 2
- 102220041275 rs587778692 Human genes 0.000 claims 2
- 201000003804 salivary gland carcinoma Diseases 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 201000005102 vulva cancer Diseases 0.000 claims 2
- 102220491290 Annexin A1_S34A_mutation Human genes 0.000 claims 1
- 102220618022 Arginine-glutamic acid dipeptide repeats protein_S93Y_mutation Human genes 0.000 claims 1
- 102220557487 Caspase-4_Y31A_mutation Human genes 0.000 claims 1
- 102220498105 Electron transfer flavoprotein subunit beta_N53A_mutation Human genes 0.000 claims 1
- 102220486715 Gap junction beta-2 protein_M34A_mutation Human genes 0.000 claims 1
- 102220593911 HLA class I histocompatibility antigen, alpha chain E_V97A_mutation Human genes 0.000 claims 1
- 101001115218 Homo sapiens Ubiquitin-40S ribosomal protein S27a Proteins 0.000 claims 1
- 102220475982 Keratin, type I cytoskeletal 10_Q24A_mutation Human genes 0.000 claims 1
- 102220497573 Leukotriene B4 receptor 1_N52A_mutation Human genes 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 102220486635 Mannose-1-phosphate guanyltransferase beta_S56A_mutation Human genes 0.000 claims 1
- 102220573906 Natural resistance-associated macrophage protein 2_N89A_mutation Human genes 0.000 claims 1
- 102220475756 Probable ATP-dependent RNA helicase DDX6_S30A_mutation Human genes 0.000 claims 1
- 102220500205 Ragulator complex protein LAMTOR4_R29A_mutation Human genes 0.000 claims 1
- 102220474389 Retinoic acid receptor RXR-alpha_S27A_mutation Human genes 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 102220477731 Tumor necrosis factor receptor superfamily member 13C_L28A_mutation Human genes 0.000 claims 1
- 102220469752 Voltage-dependent L-type calcium channel subunit beta-2_G50D_mutation Human genes 0.000 claims 1
- 102220479831 Voltage-dependent L-type calcium channel subunit beta-2_P55K_mutation Human genes 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 190000008236 carboplatin Chemical compound 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000003013 cytotoxicity Effects 0.000 claims 1
- 231100000135 cytotoxicity Toxicity 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000006882 induction of apoptosis Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 229960004768 irinotecan Drugs 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000006659 positive regulation of apoptotic process Effects 0.000 claims 1
- 102200153431 rs1060501000 Human genes 0.000 claims 1
- 102220164283 rs141738168 Human genes 0.000 claims 1
- 102220244279 rs373241693 Human genes 0.000 claims 1
- 102220098908 rs774768866 Human genes 0.000 claims 1
- 102220280441 rs776730435 Human genes 0.000 claims 1
- 102220072507 rs794729056 Human genes 0.000 claims 1
- 102220100736 rs878854061 Human genes 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 230000005909 tumor killing Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64955005P | 2005-02-02 | 2005-02-02 | |
| US60/649,550 | 2005-02-02 | ||
| US11/344,564 | 2006-01-30 | ||
| US11/344,564 US8029783B2 (en) | 2005-02-02 | 2006-01-30 | DR5 antibodies and articles of manufacture containing same |
| PCT/US2006/003577 WO2006083971A2 (en) | 2005-02-02 | 2006-01-31 | Dr5 antibodies and uses thereof |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012239879A Division JP2013027407A (ja) | 2005-02-02 | 2012-10-31 | Ｄｒ５抗体およびその使用 |
| JP2015091261A Division JP2015133985A (ja) | 2005-02-02 | 2015-04-28 | Ｄｒ５抗体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008532487A JP2008532487A (ja) | 2008-08-21 |
| JP2008532487A5 true JP2008532487A5 (enExample) | 2009-02-26 |
| JP5886509B2 JP5886509B2 (ja) | 2016-03-16 |
Family
ID=36777882
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007554188A Active JP5886509B2 (ja) | 2005-02-02 | 2006-01-31 | Ｄｒ５抗体およびその使用 |
| JP2012239879A Pending JP2013027407A (ja) | 2005-02-02 | 2012-10-31 | Ｄｒ５抗体およびその使用 |
| JP2015091261A Pending JP2015133985A (ja) | 2005-02-02 | 2015-04-28 | Ｄｒ５抗体およびその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012239879A Pending JP2013027407A (ja) | 2005-02-02 | 2012-10-31 | Ｄｒ５抗体およびその使用 |
| JP2015091261A Pending JP2015133985A (ja) | 2005-02-02 | 2015-04-28 | Ｄｒ５抗体およびその使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US8029783B2 (enExample) |
| EP (1) | EP1844077B1 (enExample) |
| JP (3) | JP5886509B2 (enExample) |
| KR (1) | KR101297467B1 (enExample) |
| CN (1) | CN101247825B (enExample) |
| AT (1) | ATE526987T1 (enExample) |
| AU (1) | AU2006210779B2 (enExample) |
| BR (1) | BRPI0606891A2 (enExample) |
| CA (1) | CA2594918C (enExample) |
| ES (1) | ES2374301T3 (enExample) |
| IL (1) | IL184617A (enExample) |
| MX (1) | MX2007009215A (enExample) |
| NO (1) | NO341791B1 (enExample) |
| NZ (1) | NZ556478A (enExample) |
| RU (1) | RU2458072C2 (enExample) |
| WO (1) | WO2006083971A2 (enExample) |
Families Citing this family (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2490280A1 (en) | 2002-07-01 | 2004-01-08 | Human Genome Sciences, Inc. | Antibodies that specifically bind to reg iv |
| EP1756162A1 (en) | 2004-03-23 | 2007-02-28 | Biogen Idec MA Inc. | Receptor coupling agents and therapeutic uses thereof |
| KR100847010B1 (ko) | 2006-07-05 | 2008-07-17 | 아주대학교산학협력단 | 세포사멸 수용체 5 (ｄｒ5)에 특이적으로 결합하는 항체 및이를 포함하는 암 예방 또는 치료용 조성물 |
| WO2009009523A2 (en) | 2007-07-09 | 2009-01-15 | Genentech, Inc. | Prevention of disulfide bond reduction during recombinant production of polypeptides |
| EP2177230A4 (en) * | 2007-08-09 | 2011-04-27 | Daiichi Sankyo Co Ltd | IMMUNOLIPOSOM AS INDUCTOR OF APOPTOSIS INTO DEATH DOMAIN-CONTAINING RECEPTOR EXPRESSING CELL |
| WO2010047509A2 (ko) * | 2008-10-24 | 2010-04-29 | 아주대학교 산학협력단 | 친화도와 안정성이 향상된 항 ｄｒ5 항체, 및 이를 포함하는 암 예방 또는 치료용 조성물 |
| US8628927B2 (en) | 2008-11-07 | 2014-01-14 | Sequenta, Inc. | Monitoring health and disease status using clonotype profiles |
| US9528160B2 (en) | 2008-11-07 | 2016-12-27 | Adaptive Biotechnolgies Corp. | Rare clonotypes and uses thereof |
| GB2483810B (en) | 2008-11-07 | 2012-09-05 | Sequenta Inc | Methods for correlating clonotypes with diseases in a population |
| US9365901B2 (en) | 2008-11-07 | 2016-06-14 | Adaptive Biotechnologies Corp. | Monitoring immunoglobulin heavy chain evolution in B-cell acute lymphoblastic leukemia |
| US8748103B2 (en) | 2008-11-07 | 2014-06-10 | Sequenta, Inc. | Monitoring health and disease status using clonotype profiles |
| US9506119B2 (en) | 2008-11-07 | 2016-11-29 | Adaptive Biotechnologies Corp. | Method of sequence determination using sequence tags |
| PT2387627E (pt) | 2009-01-15 | 2016-06-03 | Adaptive Biotechnologies Corp | Determinação do perfil de imunidade adaptativa e métodos de geração de anticorpos monoclonais |
| WO2010138725A1 (en) * | 2009-05-28 | 2010-12-02 | Amgen Inc. | Treatment of pancreatic cancer using a dr5 agonist in combination with gemcitabine |
| WO2010146059A2 (en) | 2009-06-16 | 2010-12-23 | F. Hoffmann-La Roche Ag | Biomarkers for igf-1r inhibitor therapy |
| JP2012531202A (ja) | 2009-06-25 | 2012-12-10 | フレッド ハチンソン キャンサー リサーチ センター | 適応免疫を測定する方法 |
| WO2011004899A1 (en) * | 2009-07-06 | 2011-01-13 | Takeda Pharmaceutical Company Limited | Cancerous disease modifying antibodies |
| SI2464725T2 (sl) | 2009-08-11 | 2025-06-30 | F. Hoffmann-La Roche Ag | Proizvodnja beljakovin v medijih za celične kulture brez glutamina |
| GB0914691D0 (en) | 2009-08-21 | 2009-09-30 | Lonza Biologics Plc | Immunoglobulin variants |
| CA2775350A1 (en) * | 2009-09-24 | 2011-03-31 | Seattle Genetics, Inc. | Dr5 ligand drug conjugates |
| KR101508043B1 (ko) | 2009-09-29 | 2015-04-06 | 로슈 글리카트 아게 | 이중특이적 사멸 수용체 아고니스트성 항체 |
| KR20120101050A (ko) | 2009-11-05 | 2012-09-12 | 더 유에이비 리서치 파운데이션 | 기저형 유전자형 암의 치료 방법 |
| WO2011084623A1 (en) | 2009-12-16 | 2011-07-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Method of sensitizing cancer cells to the cytotoxic effects of death receptor ligands in cancer treatment |
| NZ602368A (en) | 2010-02-12 | 2014-10-31 | Pharmascience Inc | Iap bir domain binding compounds |
| US20130064838A1 (en) * | 2010-05-14 | 2013-03-14 | Amgen Inc. | Enhanced death receptor agonists |
| NZ607615A (en) * | 2010-08-05 | 2015-03-27 | Anaptysbio Inc | Antibodies directed against il-17 |
| CN103282495B (zh) | 2010-10-29 | 2017-06-09 | 第一三共株式会社 | 新的抗dr5抗体 |
| US9428565B2 (en) | 2011-01-31 | 2016-08-30 | The General Hospital Corporation | Treatment and bioluminescent visualization using multimodal TRAIL molecules |
| CA2830349C (en) | 2011-03-17 | 2019-07-16 | The University Of Birmingham | Re-directed immunotherapy |
| MX2013012716A (es) * | 2011-05-03 | 2014-03-21 | Genentech Inc | Agentes de disociacion vascular y sus usos. |
| US10385475B2 (en) | 2011-09-12 | 2019-08-20 | Adaptive Biotechnologies Corp. | Random array sequencing of low-complexity libraries |
| EP2768982A4 (en) | 2011-10-21 | 2015-06-03 | Adaptive Biotechnologies Corp | QUANTIFICATION OF ADAPTIVE IMMUNOCELL GENOMES IN A COMPLEX MIX OF CELLS |
| AU2012347460B2 (en) | 2011-12-09 | 2017-05-25 | Adaptive Biotechnologies Corporation | Diagnosis of lymphoid malignancies and minimal residual disease detection |
| US9499865B2 (en) | 2011-12-13 | 2016-11-22 | Adaptive Biotechnologies Corp. | Detection and measurement of tissue-infiltrating lymphocytes |
| JP6302847B2 (ja) | 2012-03-05 | 2018-03-28 | アダプティヴ バイオテクノロジーズ コーポレーション | 頻度が一致したサブユニットからの、対をなす免疫受容体鎖の決定 |
| JP6219923B2 (ja) * | 2012-03-28 | 2017-10-25 | アムジェン インコーポレイテッド | Ｄｒ５受容体アゴニストの組み合わせ |
| ES2711156T3 (es) | 2012-05-08 | 2019-04-30 | Adaptive Biotechnologies Corp | Método para medir y calibrar el sesgo de amplificación en reacciones de PCR multiplexadas |
| US9500639B2 (en) | 2012-07-18 | 2016-11-22 | Theranos, Inc. | Low-volume coagulation assay |
| WO2014018113A1 (en) | 2012-07-24 | 2014-01-30 | The General Hospital Corporation | Oncolytic virus therapy for resistant tumors |
| EP2890720B1 (en) * | 2012-08-30 | 2019-07-17 | The General Hospital Corporation | Compositions and methods for treating cancer |
| EP2904111B1 (en) | 2012-10-01 | 2017-12-06 | Adaptive Biotechnologies Corporation | Immunocompetence assessment by adaptive immune receptor diversity and clonality characterization |
| UA118028C2 (uk) * | 2013-04-03 | 2018-11-12 | Рош Глікарт Аг | Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування |
| ES2732907T3 (es) * | 2013-05-03 | 2019-11-26 | Fujifilm Diosynth Biotechnologies Uk Ltd | Procedimiento de expresión |
| US9708657B2 (en) | 2013-07-01 | 2017-07-18 | Adaptive Biotechnologies Corp. | Method for generating clonotype profiles using sequence tags |
| WO2015077605A1 (en) | 2013-11-25 | 2015-05-28 | Seattle Genetics, Inc. | Preparing antibodies from cho cell cultures for conjugation |
| US20170292149A1 (en) | 2014-03-05 | 2017-10-12 | Adaptive Biotechnologies Corporation | Methods using randomer-containing synthetic molecules |
| US11299528B2 (en) | 2014-03-11 | 2022-04-12 | D&D Pharmatech Inc. | Long acting TRAIL receptor agonists for treatment of autoimmune diseases |
| US10066265B2 (en) | 2014-04-01 | 2018-09-04 | Adaptive Biotechnologies Corp. | Determining antigen-specific t-cells |
| ES2777529T3 (es) | 2014-04-17 | 2020-08-05 | Adaptive Biotechnologies Corp | Cuantificación de genomas de células inmunitarias adaptativas en una mezcla compleja de células |
| US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
| WO2016069886A1 (en) | 2014-10-29 | 2016-05-06 | Adaptive Biotechnologies Corporation | Highly-multiplexed simultaneous detection of nucleic acids encoding paired adaptive immune receptor heterodimers from many samples |
| US10246701B2 (en) | 2014-11-14 | 2019-04-02 | Adaptive Biotechnologies Corp. | Multiplexed digital quantitation of rearranged lymphoid receptors in a complex mixture |
| CA2968543C (en) | 2014-11-25 | 2024-04-02 | Adaptive Biotechnologies Corporation | Characterization of adaptive immune response to vaccination or infection using immune repertoire sequencing |
| SG11201705632UA (en) * | 2015-01-08 | 2017-08-30 | Kyowa Hakko Kirin Co Ltd | Bispecific antibody binding to trailr2 and psma |
| US10689449B2 (en) | 2015-01-20 | 2020-06-23 | Igm Biosciences, Inc. | Multimeric death domain-containing receptor-5 (DR5) antibodies and uses thereof |
| AR100680A1 (es) * | 2015-01-26 | 2016-10-26 | Macrogenics Inc | Anticuerpos anti-dr5 y moléculas que comprenden dominios de unión de dr5 de los mismos |
| AU2015380455A1 (en) | 2015-01-26 | 2017-08-03 | Macrogenics, Inc. | Multivalent molecules comprising DR5-binding domains |
| WO2016138122A1 (en) | 2015-02-24 | 2016-09-01 | Adaptive Biotechnologies Corp. | Methods for diagnosing infectious disease and determining hla status using immune repertoire sequencing |
| WO2016161273A1 (en) | 2015-04-01 | 2016-10-06 | Adaptive Biotechnologies Corp. | Method of identifying human compatible t cell receptors specific for an antigenic target |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| US20180333491A1 (en) * | 2015-08-19 | 2018-11-22 | Sinotau Pharmaceuticals Group | Trail receptor-binding agents and uses of same |
| EP3368074A2 (en) | 2015-10-30 | 2018-09-05 | Hoffmann-La Roche AG | Anti-factor d antibodies and conjugates |
| WO2017075484A2 (en) * | 2015-10-30 | 2017-05-04 | Galaxy Biotech, Llc | Highly potent antibodies binding to death receptor 4 and death receptor 5 |
| CA3008392C (en) | 2015-12-17 | 2021-11-09 | The Johns Hopkins University | Ameliorating systemic sclerosis with death receptor agonists |
| US10849912B2 (en) | 2016-02-09 | 2020-12-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Method of sensitizing cancer cells to the cytotoxic effects of apoptosis inducing ligands in cancer treatment |
| EP3439687A1 (en) | 2016-04-07 | 2019-02-13 | The Johns Hopkins University | Compositions and methods for treating pancreatitis and pain with death receptor agonists |
| US10428325B1 (en) | 2016-09-21 | 2019-10-01 | Adaptive Biotechnologies Corporation | Identification of antigen-specific B cell receptors |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| EP3360898A1 (en) | 2017-02-14 | 2018-08-15 | Boehringer Ingelheim International GmbH | Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer |
| KR101926834B1 (ko) * | 2017-03-21 | 2018-12-07 | 동아에스티 주식회사 | 항-dr5 항체 및 그의 용도 |
| RU2019142330A (ru) | 2017-06-30 | 2021-07-30 | Займворкс, Инк. | Стабилизированные химерные fab |
| KR101951025B1 (ko) * | 2017-08-17 | 2019-02-21 | 서울대학교산학협력단 | 세포사멸 수용체 저해제를 유효성분으로 포함하는 cx3cl1 케모카인 과발현으로 인한 질환 예방 또는 치료용 조성물 |
| CN109810193B (zh) * | 2017-11-21 | 2020-11-03 | 深圳市中科艾深医药有限公司 | 抗dr5的抗体及其制备方法和应用 |
| WO2019100194A1 (zh) * | 2017-11-21 | 2019-05-31 | 深圳先进技术研究院 | 抗dr5的抗体及其制备方法和应用 |
| WO2019100193A1 (zh) * | 2017-11-21 | 2019-05-31 | 深圳先进技术研究院 | 抗dr5的抗体及其制备方法和应用 |
| CN109810194B (zh) * | 2017-11-21 | 2020-11-03 | 深圳市中科艾深医药有限公司 | 抗dr5的抗体及其制备方法和应用 |
| US11254980B1 (en) | 2017-11-29 | 2022-02-22 | Adaptive Biotechnologies Corporation | Methods of profiling targeted polynucleotides while mitigating sequencing depth requirements |
| CN109957025A (zh) * | 2017-12-25 | 2019-07-02 | 深圳宾德生物技术有限公司 | 一种靶向dr5的单链抗体、嵌合抗原受体t细胞及其制备方法和应用 |
| GB201800994D0 (en) * | 2018-01-22 | 2018-03-07 | Ucl Business Plc | Combination therapeutics |
| WO2019173499A1 (en) | 2018-03-06 | 2019-09-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | 17-beta-hydroxywithanolides and use thereof in treating cancer |
| EP3896154A4 (en) * | 2018-06-13 | 2022-03-09 | Genex Health Co.,Ltd | PRIMARY CELL OF SOLID TUMOR IN COLORECTAL CANCER AND METHODS FOR CULTIVATION OF PRIMARY TUMOR CELL FROM ASCITES IN COLORECTAL CANCER AND RELEVANT REAGENT |
| AU2019402097A1 (en) | 2018-12-17 | 2021-06-10 | Revitope Limited | Twin immune cell engager |
| EP4277706A1 (en) | 2021-01-15 | 2023-11-22 | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis | Inducers of senescence, in combination with a selective death receptor 5 (dr5) agonist, for use in a method of treating cancer |
| CN113493510A (zh) * | 2021-07-07 | 2021-10-12 | 上海交通大学 | 一种牛源抗金黄色葡萄球菌LukD毒力因子的单链抗体及其制备和应用 |
| CN117285643A (zh) | 2022-06-16 | 2023-12-26 | 清华大学 | 一种相变调节套件及其用途 |
| TW202528350A (zh) * | 2023-11-10 | 2025-07-16 | 大陸商信達生物製藥（蘇州）有限公司 | 抗ｄｒ５和ｃｅａｃａｍ５的雙特異性抗體及其用途 |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
| WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
| US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
| US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
| US4873191A (en) | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US4736866B1 (en) | 1984-06-22 | 1988-04-12 | Transgenic non-human mammals | |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| EP0435911B1 (en) | 1988-09-23 | 1996-03-13 | Cetus Oncology Corporation | Cell culture medium for enhanced cell growth, culture longevity and product expression |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5047335A (en) | 1988-12-21 | 1991-09-10 | The Regents Of The University Of Calif. | Process for controlling intracellular glycosylation of proteins |
| ATE144793T1 (de) | 1989-06-29 | 1996-11-15 | Medarex Inc | Bispezifische reagenzien für die aids-therapie |
| DE10399023I2 (de) | 1989-09-12 | 2006-11-23 | Ahp Mfg B V | TFN-bindende Proteine |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5278229A (en) * | 1990-02-01 | 1994-01-11 | Nippon Gohsei Kagaku Kogyo Kabushiki Kaisha | Polyolefin composition and the use thereof |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| US5278299A (en) | 1991-03-18 | 1994-01-11 | Scripps Clinic And Research Foundation | Method and composition for synthesizing sialylated glycosyl compounds |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| JP3540315B2 (ja) | 1991-09-23 | 2004-07-07 | メディカル リサーチ カウンシル | キメラ抗体の製造−組合せアプローチ |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| AU3144193A (en) | 1991-11-21 | 1993-06-15 | Board Of Trustees Of The Leland Stanford Junior University | Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases |
| ATE149570T1 (de) | 1992-08-17 | 1997-03-15 | Genentech Inc | Bispezifische immunoadhesine |
| ES2091684T3 (es) | 1992-11-13 | 1996-11-01 | Idec Pharma Corp | Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b. |
| AU6852594A (en) | 1993-06-03 | 1995-01-03 | Therapeutic Antibodies Inc. | Production of antibody fragments |
| DE69533863T2 (de) | 1994-02-04 | 2006-02-16 | Bio Merieux | MSRV1 Virus der mit Multipler Sklerose verbunden ist, seine nukleären Bestandteile und Verwendungen |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| US6113898A (en) | 1995-06-07 | 2000-09-05 | Idec Pharmaceuticals Corporation | Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies |
| US6284236B1 (en) | 1995-06-29 | 2001-09-04 | Immunex Corporation | Cytokine that induces apoptosis |
| KR101004174B1 (ko) | 1995-06-29 | 2010-12-24 | 임뮤넥스 코포레이션 | 세포소멸을 유도하는 시토킨 |
| US6998116B1 (en) | 1996-01-09 | 2006-02-14 | Genentech, Inc. | Apo-2 ligand |
| US6030945A (en) | 1996-01-09 | 2000-02-29 | Genentech, Inc. | Apo-2 ligand |
| BR9612752A (pt) | 1996-10-25 | 2000-01-18 | Human Genome Sciences Inc | Neutrocina |
| WO1998025986A1 (en) | 1996-12-13 | 1998-06-18 | Du Pont-Toray Company, Ltd. | Polyestercarbonate-polyurethaneurea fibers |
| WO1998028424A2 (en) | 1996-12-23 | 1998-07-02 | Immunex Corporation | Receptor activator of nf-kappa b, receptor is member of tnf receptor superfamily |
| ATE362982T1 (de) | 1997-01-28 | 2007-06-15 | Human Genome Sciences Inc | ßDEATH-DOMAINß-ENTHALTENDER REZEPTOR 4 (DR4), EIN MITGLIED DER TNF-REZEPTOR SUPERFAMILIE, WELCHER AN TRAIL (APO-2L) BINDET |
| US6433147B1 (en) | 1997-01-28 | 2002-08-13 | Human Genome Sciences, Inc. | Death domain containing receptor-4 |
| US6072047A (en) | 1997-02-13 | 2000-06-06 | Immunex Corporation | Receptor that binds trail |
| US20020160446A1 (en) * | 2000-11-14 | 2002-10-31 | Holtzman Douglas A. | Novel genes encoding proteins having prognostic diagnostic preventive therapeutic and other uses |
| US20010010924A1 (en) | 1997-03-14 | 2001-08-02 | Keith Charles Deen | Tumor necrosis factor related receptor, tr6 polynecleotides |
| US6313269B1 (en) | 1997-03-14 | 2001-11-06 | Smithkline Beecham Corporation | Tumor necrosis factor related receptor, TR6 |
| NZ337795A (en) | 1997-03-17 | 2001-06-29 | Human Genome Sciences Inc | Death domain containing receptor 5 and it's use in the treatment of DR5 related disease |
| US6872568B1 (en) | 1997-03-17 | 2005-03-29 | Human Genome Sciences, Inc. | Death domain containing receptor 5 antibodies |
| CA2287085A1 (en) | 1997-04-16 | 1998-10-22 | Millennium Biotherapeutics, Inc. | Tumor necrosis factor receptor related proteins tango-63d and tango-63e |
| BR9808545A (pt) | 1997-04-16 | 2000-05-23 | Amgen Inc | ácido nucleico isolado, vetor de expressão, célula hospedeira, processos para produzir uma proteìna de ligação da osteoprotegerina, para detectar a presença de uma proteìna de ligação à osteoprotegerina em uma amostra biológica, para avaliar a capacidade de um composto candidato de ligar-se a uma proteìna de ligação da osteoprotegerina e de um composto de teste para aumentar ou reduzir a ligação da proteìna de ligação da osteoprotegerina a odar, para regular a expressão de uma proteìna de ligação da osteoprotegerina em um animal e para prevenir ou tratar de doença óssea em um mamìfero, polipeptìdeo, protéina de ligação da osteroprotegerina purificada e isolada, ou seu fragmento, análogo ou derivado, e, anticorpo ou seu fragmento |
| US5896768A (en) * | 1997-05-15 | 1999-04-27 | Ut Automotive Dearborn, Inc. | Electronic child security door lock system |
| US6342369B1 (en) | 1997-05-15 | 2002-01-29 | Genentech, Inc. | Apo-2-receptor |
| ES2293682T5 (es) * | 1997-05-15 | 2011-11-17 | Genentech, Inc. | Anticuerpo anti-apo2. |
| WO1999002653A1 (en) | 1997-07-11 | 1999-01-21 | Trustees Of The University Of Pennsylvania | Nucleic acid encoding a novel chemotherapy-induced protein, and methods of use |
| WO1999009165A1 (en) | 1997-08-15 | 1999-02-25 | Idun Pharmaceuticals, Inc. | Trail receptors, nucleic acids encoding the same, and methods of use thereof |
| AU9376498A (en) | 1997-09-05 | 1999-03-22 | University Of Washington | Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents |
| JP2002508962A (ja) | 1998-01-15 | 2002-03-26 | ジェネンテク・インコーポレイテッド | Ａｐｏ−２リガンド |
| US6468532B1 (en) | 1998-01-22 | 2002-10-22 | Genentech, Inc. | Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates |
| IL137176A0 (en) | 1998-01-26 | 2001-07-24 | Genentech Inc | Antibodies to 4dr and uses thereof |
| US6252050B1 (en) | 1998-06-12 | 2001-06-26 | Genentech, Inc. | Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method |
| EP1086138B1 (en) | 1998-06-12 | 2009-09-23 | Genentech, Inc. | Monoclonal antibodies, cross-reactive antibodies and method for producing the same |
| BR0008758A (pt) * | 1999-01-15 | 2001-12-04 | Genentech Inc | Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante |
| GB9908533D0 (en) * | 1999-04-14 | 1999-06-09 | Novartis Ag | Organic compounds |
| DK1181319T3 (da) | 1999-05-28 | 2009-08-17 | Genentech Inc | Kimære DR4-antistoffer og anvendelser deraf |
| PT1192185E (pt) | 1999-06-09 | 2006-11-30 | Genentech Inc | Sinergismo de agonista do receptor de apo-2l e cpt-11 |
| JP5118796B2 (ja) | 1999-06-28 | 2013-01-16 | ジェネンテック， インコーポレイテッド | 二価の金属イオンを利用したＡｐｏ−２リガンドの製造方法 |
| CN100341860C (zh) | 2000-01-20 | 2007-10-10 | 罗狄亚化学公司 | 制备轻度着色的支化多异氰酸酯的方法及所得到的组合物 |
| JP2001259961A (ja) | 2000-03-15 | 2001-09-25 | Disco Abrasive Syst Ltd | 加工装置 |
| TWI318983B (en) | 2000-05-02 | 2010-01-01 | Uab Research Foundation | An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
| US7279160B2 (en) | 2000-05-02 | 2007-10-09 | The Uab Research Foundation | Combinations of DR5 antibodies and other therapeutic agents |
| IL153948A0 (en) | 2000-07-27 | 2003-07-31 | Genentech Inc | Apo-2l receptor agonist and cpt-11 synergism |
| US7960670B2 (en) * | 2005-05-03 | 2011-06-14 | Kla-Tencor Corporation | Methods of and apparatuses for measuring electrical parameters of a plasma process |
| JP3665316B2 (ja) | 2001-05-18 | 2005-06-29 | 麒麟麦酒株式会社 | 抗ｔｒａｉｌ−ｒ抗体 |
| DK1572874T3 (da) | 2001-05-25 | 2013-12-16 | Human Genome Sciences Inc | Antistoffer, der immunospecifikt binder til TRAIL receptorer |
| EP1409544B1 (en) | 2001-07-03 | 2009-06-17 | Genentech, Inc. | Human dr4 antibodies and uses thereof |
| NZ533164A (en) | 2001-11-01 | 2008-09-26 | Uab Research Foundation | Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents |
| ES2357225T3 (es) | 2001-11-01 | 2011-04-20 | Uab Research Foundation | Combinaciones de anticuerpos anti-dr5 y anticuerpos anti-dr4 y otros agentes terapéuticos. |
| WO2003042367A2 (en) | 2001-11-14 | 2003-05-22 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to trail receptors |
| AU2002361784A1 (en) | 2001-12-20 | 2003-07-09 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to trail receptors |
| CA2523716C (en) | 2003-05-31 | 2014-11-25 | Micromet Ag | Human anti-human cd3 binding molecules |
| KR20070010046A (ko) | 2004-04-06 | 2007-01-19 | 제넨테크, 인크. | Ｄｒ5 항체 및 그의 용도 |
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| PE20071101A1 (es) | 2005-08-31 | 2007-12-21 | Amgen Inc | Polipeptidos y anticuerpos |
| CN101074261A (zh) | 2006-04-30 | 2007-11-21 | 北京同为时代生物技术有限公司 | Trail受体1和/或trail受体2特异性抗体及其应用 |
-
2006
- 2006-01-30 US US11/344,564 patent/US8029783B2/en active Active
- 2006-01-31 BR BRPI0606891-0A patent/BRPI0606891A2/pt not_active Application Discontinuation
- 2006-01-31 KR KR1020077019924A patent/KR101297467B1/ko active Active
- 2006-01-31 AU AU2006210779A patent/AU2006210779B2/en not_active Ceased
- 2006-01-31 CN CN200680009970.1A patent/CN101247825B/zh active Active
- 2006-01-31 CA CA2594918A patent/CA2594918C/en active Active
- 2006-01-31 WO PCT/US2006/003577 patent/WO2006083971A2/en not_active Ceased
- 2006-01-31 RU RU2007132876/10A patent/RU2458072C2/ru active
- 2006-01-31 ES ES06734171T patent/ES2374301T3/es active Active
- 2006-01-31 AT AT06734171T patent/ATE526987T1/de active
- 2006-01-31 MX MX2007009215A patent/MX2007009215A/es active IP Right Grant
- 2006-01-31 EP EP06734171A patent/EP1844077B1/en active Active
- 2006-01-31 NZ NZ556478A patent/NZ556478A/en not_active IP Right Cessation
- 2006-01-31 JP JP2007554188A patent/JP5886509B2/ja active Active
- 2006-10-10 US US11/546,133 patent/US8030023B2/en active Active
-
2007
- 2007-07-15 IL IL184617A patent/IL184617A/en active IP Right Grant
- 2007-08-31 NO NO20074446A patent/NO341791B1/no unknown
-
2011
- 2011-09-07 US US13/227,391 patent/US8409570B2/en active Active
-
2012
- 2012-10-31 JP JP2012239879A patent/JP2013027407A/ja active Pending
-
2015
- 2015-04-28 JP JP2015091261A patent/JP2015133985A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008532487A5 (enExample) | ||
| RU2007132876A (ru) | Антитела к dr5 и их применения | |
| JP7682789B2 (ja) | Ｂ７－Ｈ３のＩｇＶドメインに対するモノクローナル抗体及びその使用 | |
| JP7118117B2 (ja) | 抗体－薬物コンジュゲートの選択的製造方法 | |
| Lou et al. | Antibody variable region engineering for improving cancer immunotherapy | |
| TWI708788B (zh) | 雙特異性抗體 | |
| JP5324593B2 (ja) | マクロファージ刺激タンパク質受容体（ｒｏｎ）の阻害およびその処置の方法 | |
| JP2020503001A5 (enExample) | ||
| KR20170010764A (ko) | 신규한 항-ｒｎｆ43 항체 및 사용 방법 | |
| JP2017500028A (ja) | 新規の抗ｄｐｅｐ３抗体および使用方法 | |
| KR20240145470A (ko) | 항-tigit 항체 및 항-pd-1/항-vegfa 이중특이적 항체를 포함하는 약제학적 조성물 및 용도 | |
| JP2013527762A5 (enExample) | ||
| EP4190816A1 (en) | Anti-cd47 monoclonal antibody and use thereof | |
| JPWO2021139777A5 (enExample) | ||
| CN106714822A (zh) | 用于治疗癌症的组合治疗 | |
| US20220119545A1 (en) | Cdcp1-targeted therapies | |
| US20230340119A1 (en) | Composition of triax antibodies and method of making and using thereof | |
| TW201605480A (zh) | 抗ｅｆｎａ４抗體－藥物結合物 | |
| KR20250026284A (ko) | 약학 조성물 및 이의 용도 | |
| JPWO2020218951A5 (enExample) | ||
| JP2022554270A (ja) | 抗ｐｄ－１抗体による癌を治療する方法 | |
| EP4406552A1 (en) | Use of anti-cd40 antibody | |
| WO2025157266A1 (zh) | 一种Nectin-4抗体及其应用 | |
| RU2024126025A (ru) | Антитела против msln и способы их применения | |
| Albrecht | Role of antibodies in cancer treatment (an overview) |